English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

BackgroundPlatelet aggregation occurs as a central role in acute coronary syndrome (ACS), and glycoprotein GP IIb/IIIa inhibitors may enhance the benefits expected from early recanalisation.AimTo compare the degree of platelet aggregation inhibition achieved by Eptifibatide versus high dose Tirofiban, and its clinical effects regarding myocardial reperfusion parameters: myocardial blush grade (MBG) and ST-segment resolution (STR) >70%, and regarding peri procedural complications, bleeding and major adverse cardiac events (MACE).MethodsBetween the period of June 2010–January 2012, 46 patients with acute myocardial infarction whose symptom onset is within 12h of presentation and ECG showing ST-segment elevation 1mm in two contiguous limb leads or 2mm in two contiguous precordial leads or acute left bundle branch block were included. Exclusion criteria were active bleeding, thrombocytopenia, bleeding diathesis, anticoagulation or thrombolitics, recent major surgery or stroke, cardiogenic shock, and pregnancy. Patients were randomized alternatively (1:1) into two groups before primary percutaneous cardiac intervention (PCI) to receive the specific glycoprotin IIb/IIIa inhibitor as follows: (I) Tirofiban group: intravenous high bolus dose of 25mcg/kg over 3min followed by maintenance infusion of 0.15mcg/kg/min. (II) Eptifibatide group: intravenous two boluses 10min apart (each one is 180mcg/kg) followed by maintenance of 2mcg/kg/min.Platelet aggregation inhibition was measured by light transmission aggregometer, angiographic assessment was done before and after final interventions for TIMI flow and myocardial blush grade before and after the procedure. Electrocardiographic assessment standard 12-lead ECG on admission, immediately after PCI. Resolution of ST segment elevation was expressed as a percentage of the initial ST segment elevation. Resolution of ⩾70% was defined as complete resolution.Clinical safety assessment was done in terms of the incidence of: bleeding complications and major adverse cardiac events (MACE): death, non-fatal myocardial infarction (MI), and target vessel revascularization (TVR).ResultsThe total patients in our study included 46 patients, 40 males (87%) and six females (13%) with a mean age of 55±10, Tirofiban group: included 23 patients, 19 males (82.5%) and four females (17.4%) with a mean age of 57±9.65. Eptifibatide group: included 23 patients, 21 males (87%) and two females (8.7%) with a mean age of 53.48±8.6.Platelet aggregation inhibition during PCI was significantly correlated with STR (p 0.013, r 0.71). The cut-off point for platelet aggregation inhibition as a predictor of STR >70% was 89.5% (sensitivity 92.3%, specificity 69.2%, PPV 75% and NPV 10%, AUC 0.87). Platelet aggregation inhibition during PCI was positively correlated with MBG (p 0.045, r 0.453). The cut-off point for platelet aggregation inhibition as a predictor of MBG 2–3 was 87.5% (sensitivity 73.6%, specificity 66.7%, PPV 93.9% and NPV 76.9%, AUC 0.81).Platelet aggregation inhibition 60min after bolus was (93.57±2.07% versus 87.62±3.2%, p<0.001) and 6h later (89.85±2.03% versus 78.5±7.07%, p<0.001) in Eptifibatide versus Tirofiban groups, respectively. Post procedural TIMI flow III was (95.7% versus 91.3%, p 1), mean MBG (2.87±0.34 versus 2.09±0.73, p<0.001) and STR >70% (56.22% versus 39.13%, p 0.005) in Eptifibatide versus Tirofiban group, respectively.There was no significant statistical difference regarding thrombocytopenia (46.73±41.48 versus 39.04±34.41, p 0.37), minor bleeding (17.4% versus 21.7%, p 0.5), major bleeding (0% versus 4.3%, p 0.5), post procedural infarction (0% versus 17.4%, p 0.12), TVR (0% versus 8.7%, p 0.24), MACE and 30days mortality (4.3% versus 13%, p 0.34) in Eptifibatide versus Tirofiban group, respectively.Conclusions•Platelet aggregation inhibition during PCI was significantly correlated with STR and MBG. Platelet aggregation inhibition cut-off point as a predictor of STR >70% was 89.5%, and as a predictor of MBG 2–3 was 87.5%.•Eptifibatide achieves better platelet aggregation inhibition 60min after bolus and 6h after PCI than high dose Tirofiban.•Eptifibatide is associated with better myocardial perfusion as indicated by post procedural mean MBG and STR >70% than high dose Tirofiban.•There was no significant differences between Eptifibatide and high dose Tirofiban regarding thrombocytopenia, major or minor bleeding, MACE and 30days mortality

Platelet aggregation inhibition by Eptifibatide versus high dose Tirofiban during primary percutaneous interventions